Dataset from Immunogenicity, Reactogenicity and Safety Study of Pediarix®, Hiberix® and Prevenar 13® Co-administered With Two Different Formulations of GSK Biologicals' HRV Vaccine (444563) in Healthy Infants 6-12 Weeks of Age

The purpose of this study is to assess if there is any immune interference between the
Porcine circovirus free (PCV-free) liquid Human rotavirus (HRV) vaccine and routine infant
vaccinations currently in use in the US, namely Pediarix®, Hiberix® and Prevenar 13® as
compared to the currently licensed lyophilized formulation of the HRV vaccine when
co-administered with the same routine vaccinations in healthy infants 6-12 weeks of age